Blockchain

Pi Squared Raises $12.5 Million in Seed Funding Led by Polychain Capital to Build a Universal ZK Circuit Powered by Proof of Proof

Champaign, Illinois, United States, July 2nd, 2024, Chainwire

 

Pi Squared, (Proof of Proof), announced the closure of their first capital raise. Led by Polychain Capital, the syndicate includes ABCDE, Bloccelerate, Generative Ventures, Robot Ventures, and Samsung Next. Angel investors include Shumo Chu, Harish Devarajan, Justin Drake, Sreeram Kanaan, Csongor Kiss, George Lambeth, Yilong Li, Calvin Liu, Lucian Mincu, Karthik Raju, and Common Prefix.

Using zero-knowledge (ZK) technology in a correct-by-construction and fundamentally unique way, Pi Squared will enable trustless remote computing, AI, and interoperable smart contracts for any blockchain or dApp. This will be made possible through the creation of a universal and disarmingly small ZK circuit that checks the integrity of mathematical proofs, which will provide verifiable-computing correctness guarantees to all languages and virtual machines (VMs) alike directly from their formal semantics, without any translation to a common language, VM, or instruction set architecture (ISA).

“Our mission is to revolutionize verifiable computing, making it universal for all languages and virtual machines, inherently correct-by-construction, and lightning-fast,” says Grigore Roșu, CEO of Pi Squared and CS Professor at University of Illinois Urbana-Champaign. “This will have many applications, including a universal settlement layer (USL) so all Blockchains, L1s and L2s, can be universal, correct, inter-operable and efficient. It does not end there, our long-term mission is to settle all science and knowledge on USL.”

“Pi Squared’s proof of proof technology will have a transformative impact across Web3 and beyond,” said Karthik Raju, GP at Polychain Capital. “Pi Squared’s universal ZK circuit will significantly increase the reach and applicability of Web3 for everyone, from builders to end users.”

Pi Squared will enable the next generation of verifiable computing that is universal and scalable with an optimally minimal trust base. The first product powered by Pi Squared is the Universal Settlement Layer (USL), an architecture for modular blockchains that enables the following characteristics:

Universality

Computations can be expressed in any high-level or virtual machine language, without the need for compilers or translators.

Provable correctness

Computations verified by the USL are mathematically proven to be correct, and any external entity can independently verify the correctness of the state of the USL.

Trust Base Minimality

USL exposes any trust assumptions in upper-layer computations for increased transparency, end-user awareness, and will minimize the trust base through correctness proofs.

App Interoperability

The USL will support interoperability between different application modules and networks (e.g. appchains).

Determinism and reproducibility

The validation is reproducible and independently verifiable by any external entity.

Pi Squared’s USL therefore provides end-to-end correctness guarantees for generic computations while minimizing the trust base underlying these computations. USL promotes verifiable computing as the standard distributed computing paradigm without requiring or promoting particular domain-specific languages (DSLs), VMs, or execution environments, all while being efficient and scalable.

Pi Squared will be presenting and exhibiting at events around EthCC in Brussels from July 8th to 11th. Attendees can listen to Pi Squared’s CEO, Grigore Roșu, speak at Restaking & Infra Day on July 8th and L2con on July 9th.

About Pi Squared

Pi Squared means ZK proofs of mathematical proofs. Pi Squared uses ZK technology in a correct-by-construction and fundamentally unique way. A universal and disarmingly small ZK circuit provides verifiable-computing correctness guarantees to all languages and VMs alike, without any translation to a common language, VM, or ISA. Pi Squared is led by UIUC professor Grigore Rosu, founder of the K framework and of Runtime Verification, and consists of researchers and founders of successful projects in formal methods, blockchain, and AI/ML.

To book a meeting with Pi Squared’s CEO and team, attendees can reach out to [email protected].

To learn more about Pi Squared’s vision and Proof of Proof, visit pi2.network and follow Pi Squared on social media.

 

Contact

Head of Marketing
Chris Hazelton
Pi Squared Inc
[email protected]

PostAd_coinrule_banner728x90

Leave a Comment

Your email address will not be published. Required fields are marked *

*

Equasens: 2024 half-year results

2024-09-27T16:00:00Z

Villers-lès-Nancy, 27 September 2024 - 6:00 p.m. (CET)

PRESS RELEASE

2024 half-year results

  • Group results impacted by weaker economic conditions and continuing investment efforts in H1:
    • Revenue: €108.0m, -4.1%
    • Current Operating Income: €20.9m, -24.1%
  • Net Profit attributable to the Group: €17.2m, -21.8%
  • Though with a profit margin that continues to be very positive:
    • Ratio of Current Operating Income (COI) to Sales: 19.3% on a reported basis and 20.0% like-for-like
H1 RESULTS (€M)2023
reported basis
2024
reported basis
Change / Reported basisExternal growthChange / Like-for-like basis
Revenue112.6108.0-4.6-4.1%-3.7-8.3-7.4%
Current operating income (COI)27.520.9-6.6-24.1%0.0-6.7-24.3%
Net Profit22.918.1-4.8-21.0%0.0-4.8-21.1%
Net Profit attributable to the Group22.017.2-4.8-21.8%   

The financial statements for the six-month period ended 30 June 2024 were reviewed and adopted by EQUASENS' Board of Directors, chaired by Thierry Chapusot, on 27 September 2024. These interim consolidated financial statements were subject to a limited review by the Statutory Auditors.

_____

Results at 30 June 2024

H1 Current Operating Income / Division2023
reported basis
2024
reported basis
Change / Reported basisExternal growthChange / Like-for-like basis
Pharmagest18.414.1-4.3-23.5%-0.1-4.4-24.0%
Axigate Link4.64.4-0.2-4.9% -0.2-4.9%
e-Connect3.62.5-1.1-29.9% -1.1-29.9%
Medical Solutions1.30.0-1.3-100.0%0.1-1.2-92.5%
Fintech-0.4-0.10.369.3% 0.3-69.3%
Current Operating Income27.520.9-6.6-24.1%0.0-6.7-24.3%
  • PHARMAGEST division: a contraction in earnings reflecting lower sales and reinforced teams in Europe (COI/Sales: 17.2%)

The decline in the Division's operating income is mainly attributable to a reduction in sales in France in the configuration and hardware segment. In a persistently challenging economic environment, the Division continued to focus its commercial strategy on acquiring new customers and regularly rolling out new software and hardware solutions.
Despite this, recurring revenues were bolstered by the combined contribution of new SaaS offerings and contract indexation.
To accelerate the deployment of solutions in Europe, the R&D and sales teams continued to be strengthened.

  • AXIGATE LINK division: the profit margin remains high (COI/Sales: 28.6%)

Strategic investments to support the roll-out of SaaS solutions such as TitanLink for Nursing Homes in Europe, and the extension of homecare services, have temporarily weighed on the Division's results.

  • E-CONNECT division: current operating income declined in response to lower sales (COI/Sales: 45.4%)

As previously reported, H1 2023 sales and earnings were boosted by the announced discontinuation of sales of Application Reader Terminals.
The downturn in business in the first half of 2024 thus reflected the corresponding decline in sales.
Despite this unfavourable environment, the Division demonstrated its ability to adapt by maintaining a healthy profit margin based on tight cost controls.

  • MEDICAL SOLUTIONS division: a year of transition between the Ségur digital healthcare investment programme and a new software solution (COI/Sales: -)

Preparations for the Division's future involving the development of a new software platform and optimising the sales organisation led to significant investments which, in conjunction with lower sales following the end of the Ségur programme roll-out, weighed on the Division's results. Recurring revenues rose 13.7%, resulting in a gross margin of 72.8%.

  • FINTECH division: efforts to stabilise the business paid off in H1, with an improvement in earnings of €0.3m (COI/Sales: -)

Consolidated balance sheet highlights

  • Cash flow after interest and tax maintained a positive trend at €20.8m.
  • Financial investments, through acquisitions as well as capital expenditures, in particular for the EQUASENS private healthcare cloud, continued, with more than €16.0m committed in H1.
  • The net financial surplus at 30/06/2024 of €87.9m takes into account a change in presentation of IFRS 16 lease liabilities and put options for minority shareholders of €10.8m (recognised under other liabilities versus financial liabilities previously).

2024 outlook

  • The Group maintains its forecast for a return to revenue growth starting in the second half of 2024, and an acceleration in 2025 driven by current investments and an economic climate that looks set to improve, particularly for pharmacies in France.
  • The Group will continue to invest in R&D, infrastructure and sales forces in France and Europe in the second half of 2024. And while this will have a temporary impact on profitability in 2024, it should generate a return on investment from 2025 onwards.
  • With a strategy focused on patients and interoperability, the Group is ideally positioned to seize opportunities for external growth in France and Europe.

Financial calendar:

  • 1 October 2024: Presentation of H1 2024 results
  • 7 November 2024: Publication of Q3 2024 revenue
  • 6 February 2025: Publication of f Q4/FY 2024 revenue

About Group Equasens

With more than 1,300 employees, Equasens Group is today a key player in the European healthcare sector, providing software and hardware solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, hospital-at-home programmes, retirement homes, health centres) in both primary and secondary care sectors.

With operations in in France, Germany, Great Britain, Belgium, Ireland, Italy, and Luxembourg, Equasens Group today brings together healthcare professionals within a unique ecosystem in France and Europe benefiting people by making available the very best of technology.

Listed on Euronext Paris™ - Compartment B

Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable
Included in the Euronext Tech Leaders segment and the European Rising Tech label

Eligible for the Deferred Settlement Service (“Service à Réglement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME).
ISIN: FR 0012882389 – Ticker Code: EQS

Get all the news about Equasens Group www.equasens.com and on LinkedIn

CONTACTS

Analyst and Investor Relations:
Chief Administrative and Financial Officer: Frédérique Schmidt
Tel: +33 (0)3 83 15 90 67 - [email protected]

Financial communication agency:
FIN’EXTENSO - Isabelle Aprile

Tel.: +33 (0)6 17 38 61 78 - [email protected]

Attachment


GlobeNewsWire News

Recent Comments